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Abstract
Phosphatase of regenerating liver-1 (PRL-1) belongs to a unique subfamily of protein tyrosine
phosphatases (PTPases) associated with oncogenic and metastatic phenotypes. While considerable
evidence exists to supports a role for PRL-1 in promoting proliferation, the biological regulators and
effectors of PRL-1 activity remain unknown. PRL-1 activity is inhibited by disulfide bond formation
at the active site in vitro, suggesting PRL-1 may be susceptible to redox regulation in vivo. Because
PRL-1 has been observed to localize to several different subcellular locations and cellular redox
conditions vary with tissue type, age, stage of cell cycle and subcellular location, we determined the
reduction potential of the active site disulfide bond that controls phosphatase activity to better
understand the function of PRL-1 in various cellular environments. We used high-resolution solution
NMR spectroscopy to measure the potential and found it to be −364.3 ± 1.5 mV. Because normal
cellular environments range from −170 to −320 mV, we concluded that nascent PRL-1 would be
primarily oxidized inside cells. Our studies show that a significant conformational change
accompanies activation, suggesting a post-translational modification may alter the reduction
potential, conferring activity. We further demonstrate that alteration of the C-terminus renders the
protein reduced and active in vitro, implying the C-terminus is an important regulator of PRL-1
function. These data provide a basis for understanding how subcellular localization regulates the
activity of PRL-1 and, with further investigation, may help reveal how PRL-1 promotes unique
outcomes in different cellular systems, including proliferation in both normal and diseased states.
Phosphatase of Regenerating Liver (PRL) enzymes are a unique subfamily of protein tyrosine
phosphatases (PTPases) and play an important role in maintaining appropriate tyrosine
phosphorylation levels in the cell during development and tissue regeneration (1). This
subfamily includes three homologous members (PRL-1, −2 and −3) that share a high degree
of amino acid sequence identity (>75%). PRL-1 (20 kDa) was first discovered in regenerating
liver following partial hepatectomy as the product of an early-immediate response gene (2)
and has since been implicated in the repair of other tissues including neurons, oligodendrocytes
and the cerebral cortex in response to transient forebrain ischemia (3). PRLs are normally
expressed at low levels in most mature cells, while higher expression levels are observed during
embryonic development (4) and during cellular proliferation (5–9) or differentiation (5,10,
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11) depending on the cell type. Recently, PRL enzymes have gained considerable interest
because each of the three isoforms can aggressively promote cancer (12,13). Each isoform is
expressed at high concentrations in various cancer tissues and promotes cellular transformation
and tumorigenesis (14–22). A substantial amount of research is available that shows PRL-1
(8,16,17,23–26) or PRL-3 (18,27–32) expression promotes cellular motility, invasiveness, and
metastasis. Furthermore, it has been shown that during these cellular processes, PRL-1’s
critical active site cysteine (C104) is required to facilitate proliferation, motility and metastasis
(7–9,26,30,33,34). Studies examined the inactive C104S/A mutant and concluded that PTP
activity is responsible for the observed outcomes. Although phenotypic responses to PRL-1
expression and activity have been wellestablished, the exact biochemical role that PRL-1 plays
in these processes has yet to be described.
Like all PTPases, PRL enzymes accomplish the removal of phosphate from their
phosphotyrosine substrate via their CX5R active site motif (35). In this motif, the conserved
cysteine initiates the catalytic reaction by attacking the phosphorous on the incoming substrate,
while the phosphate binding loop (P-loop) and conserved arginine residue bind and position
the phosphate group (36). Unlike most cysteine residues in proteins that have pKa values near
8, the PTPase catalytic cysteine is typically deprotonated (pKa≈5) due to the partially positive
microenvironment of the active site, making it extremely reactive at physiological pH (1). The
exceptional reactivity of the thiol group required for enzyme activity also renders the catalytic
cysteine highly susceptible to oxidation (1,36). As established for PTP-1B and the
dualspecificity phosphatase PTEN, oxidation by singlet oxygen and hydroxyl radical leads to
disulfide bond formation at the nucleophilic cysteine, inactivating the enzyme (37,38). In
PRL-1, oxidation at the nucleophilic C104 abolishes PTPase activity by promoting disulfide
bond formation with C49, a spatially proximal but sequentially distal cysteine residue (36).
Disulfide bond formation is reversible in vitro and in vivo and reduction is accomplished via
reducing agents present in solution. To restore enzymatic function, reduction at the active site
must occur in order to expose the nucleophilic thiol. Reduced forms of PRL enzymes have
been isolated and characterized by NMR and X-ray crystallography (36,39–41). In vitro
activity assays and structure analyses are often performed in the presence of high
concentrations of reducing agents to prevent inactivation. Despite this precaution,
crystallization of PRL-1 produced a structure of the inactive oxidized form. No other PTPase
structure has been reported in the inactive state and many remain active in the absence of
reducing agents, suggesting that PRL-1 may be more prone to oxidation than other family
members.
Disulfide bond formation in vivo depends on the presence of reactive oxidants as well as the
redox environment of the cell, which is primarily determined by the amount of glutathione and
the ratio of its reduced to oxidized forms [GSH:GSSG] (42). The reduction potential and
capacity of a cell vary with compartment, stage of cell cycle, tissue type, age and health.
Interestingly, reports describing PRL-1’s subcellular location have been quite varied.
Localization of PRL-1 in the cell appears to be influenced by a number of factors, including
stage of cell cycle, tissue type and modification at the C-terminus (2,6,9,43). The specific roles
that PRL-1 plays at each of these locations has yet to be elucidated, but based on the data
presented here, the redox environment and modification state of PRL-1 are likely to regulate
the function of this enzyme in vivo. In the present study, we used high-resolution NMR to
determine the reduction potential of the active site disulfide bond in full-length PRL-1.
Determining the reduction potential of the disulfide bond involving the catalytic cysteine
provides a basis for understanding how subcellular localization may regulate the phosphatase
activity of PRL-1 in different types of cellular environments.
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Protein Expression and Purification
Wild-type PRL-1 and PRL-1-C170S-C171S were produced as described previously (44). To
create the PRL-1-C98A and PRL-1-C104S mutants, the human PRL-1 gene was cloned into
the pET-30 Xa/LIC vector (Novagen) and mutated using the PCR-based QuickChange method
(Stratagene). The primers used to generate the C98A and C104S mutants, 5’ to 3’, were
cgtgaagaacctggtGCTtgtattgctgttcattgc and ggttgtattgctgttcatTCCgttgcaggccttgg, respectively.
Capital letters indicate the mutated bases. PCR reactions were treated with DpnI (Promega)
for 1.5 hours at 37°C, directly transformed into Novablue GigaSingles competent cells
(Novagen) and selected on LB plates with 30 mg/mL kanamycin. Individual colonies were
cultured overnight in selective LB at 37°C, and the resultant DNA was purified using the
Qiagen MiniPrep System (Stratagene). All mutations were confirmed using bidirectional DNA
dye-terminator sequencing (Northwoods DNA, Inc., Bemidjii, MN). All variants of PRL-1
were expressed in BL21(DE3) (Novagen) cells on minimal media and purified as described
previously (45). Samples for NMR were produced from cells grown on minimal media
containing 15N ammonium chloride (Spectra Stable Isotopes). All solutions used in the
purification and analysis of samples involved in this study were sparged with Ar gas to
minimize oxidation derived from O2.
Electrospray Ionization Mass Spectrometry
ESI spectra were acquired on a Q-Tof-2 (Micromass Ltd, Manchester UK) Hybrid Mass
Spectrometer operated in MS mode and acquiring data with the time of flight analyzer de-tuned
to 8000 resolution (FWHH) for sensitivity. For whole protein ESI spectra, purified protein
samples were diluted to 1 µg/µL in untreated (“oxidizing”) 20 mM ammonium bicarbonate,
pH 8.2, and allowed to incubate at room temperature. Time points were taken on the first, fourth
and seventh day post-purification and frozen at −80°C until ready for use. Samples were
desalted on a short (3 cm × 1 mm I.D.) reversephase (RP) HPLC column (Hamilton PRP1,
Reno, NV). Samples were loaded onto the column from a 1% formic acid solution with protein
(5 µg), washed in same solution, and eluted with 90% MeOH/0.5% formic acid directly into
the ESI source. The cone voltage was 60 eV, and the voltage on the collision cell was 20 V.
Spectra were acquired over the mass range 800 to 3000 u, accumulating data for 5 seconds per
cycle.
For tryptic digests, PRL-1-WT and PRL-1-C170S-C171S were diluted to 1 mg/mL in
ammonium bicarbonate, pH 8.2, with or without 20 mM β-mercaptoethanol (BME), and trypsin
(Promega) was added in a 1:50 ratio protease:protein (w/w) and incubated at 37°C for 16 hrs.
To confirm complete digestion, samples at various time points were run on SDS-PAGE and
visualized by silver staining. Coupled to MS analysis, capillary HPLC separations were
performed using a Zorbax SBC18 RP column (5 cm × 0.32 mm I.D., 3.5 µm bead size, 300 Å
pore size) packed by Micro-Tech Scientific (Sunnyvale, CA), with a chromatograph (Waters
capLC XL, Milford, MA) that develops gradients at 10 µL/min. A linear gradient of 20 to 80%
B was applied over 120 minutes. The solvents were: A) 99% H2O, 1% MeOH, B) 99% MeOH,
1% H2O, and both contained 0.08% formic acid. Argon was admitted to the collision cell at a
pressure that attenuates the beam to about 20%. This corresponds to 16 psi on the supply
regulator or 5.3 × 10−5 mBar on a penning gauge near the collision cell. The collision cell was
operated at 8 V for maximum transmission, and spectra were acquired over the range 250 to
2000 u, accumulating data for 8 seconds per cycle.
SDS-PAGE
Post-purification, all samples were exchanged by dialysis at least 1000 fold into 50 mM sodium
phosphate, pH 7.5, with 100 mM NaCl. Protein samples at a final concentration of 1 mg/mL
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were incubated for 1 hour with varying amounts of reduced or oxidized dithiothreitol (DTT).
Oxidized DTT was obtained by incubating H2O2 with DTT at a 3:1 concentration ratio
(H2O2:DTT) and was confirmed to be complete by monitoring the absorbance at 283 nm
(46,47). After incubation, non-reducing SDS-PAGE loading buffer was added. Samples were
then heated for 6 minutes and finally run on a 12% acrylamide gel. Gels were stained using
Coomassie (R-250) and the protein bands were used to assess the relative amounts of reduced
or oxidized PRL-1.
Phosphatase Activity Assays
A standard phosphatase activity assay with p-nitrophenyl phosphate (pNPP) was used to
determine the relative activity of PRL-1 variants (35). All samples were exchanged at least
1000 fold by dialysis or using Amicon Ultra 10 kDa centrifugal filters (Millapore) into 50 mM
HEPES, pH 7.5 before being tested for phosphatase activity. Assay mixtures contained 50 mM
HEPES, pH 7.5, 20 mM p-nitrophenyl phosphate (pNPP-freshly prepared) and 0–10 mM
reduced DTT. Reactions were initiated by the addition of PRL-1 at a final concentration of 1
mg/mL and monitored for absorption at 405 nm and 37°C using a Cary 100 UV-Vis
spectrophotometer with temperature controller. Reactions were run in triplicate and on a
minimum of two independently produced protein samples, totaling at least n=6 replicates.
Relative activity was determined at 60 minutes by calculating the amount of p-nitrophenol
produced (ε=1.78×10−4 M−1·cm−1) (48). Averages of the individual runs are shown.
NMR Experiments
For structural comparisons of PRL-1 variants, samples were prepared in 50 mM sodium
phosphate buffer, 100 mM NaCl, pH 6.5, containing 5% D2O. 1H-15N Heteronuclear Single
Quantum Coherence spectra were acquired on a Bruker Avance 800 MHz spectrometer using
a cryogenic, triple resonance probe equipped with pulse field gradients. Water suppression was
accomplished using flip-back pulses. The concentrations of PRL-1-WT and PRL-1-C170S-
C171S were 1.0 mM and the spectra were acquired in 8 scans with 2048 points in 1H and 128*
increments in 15N. The concentration of PRL-1-C98A was 3 mM and the spectra were acquired
in 2 scans with 2048 points in 1H and 256* increments in 15N. Sample reduction was
accomplished by the addition of 10 mM DTT at least 72 hours prior to spectral acquisition.
All spectra were obtained at 37°C.
For the redox titration, the method previously published by Piotukh et al. (2007) was followed
(49). Briefly, PRL-1-C98A was prepared in 50 mM sodium phosphate, 100 mM NaCl, pH 7.5,
containing 5% D2O at a final concentration of 0.3 mM. As judged by SDS-PAGE, PRL-1-
C98A was fully oxidized by adding 5 mM oxidized DTT (DTT oxidation was verified as
described above). The sample was then titrated with increasing amounts of reduced DTT (1–
200 mM) and a 1H-15N HSQC spectrum was taken at each point. Spectra were collected on a
Bruker Avance 800 spectrometer using a cryogenic, triple resonance probe equipped with pulse
field gradients. All spectra were obtained at 37°C and acquired in at least 16 scans with 2048
points in 1H and 256* increments in 15N. For both studies, 1H chemical shifts were referenced
with respect to an external DSS standard in D2O. Indirect referencing relative to 1H was
determined for 13C and 15N, assuming ratios 13C/1H = 0.251449530 and 15N/1H = 0.101329118
(50). nmrPipe and SPARKY were used for data processing and spectral analysis (51, 52).
Determining the Reduction Potential of PRL-1
Following the method by Piotukh et al. (2007) to determine the reduction potential of PRL-1,
the heights of several well-resolved peaks in each NMR spectrum were obtained using
SPARKY and plotted versus the corresponding halfcell potential of DTT (49). The half-cell
potential of DTT was calculated according to the Nernst equation (42),
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where R is the universal gas constant (8.3145 J K−1 mol−1), T is the temperature in Kelvin,
n=2 for the two-electron reduction, and F is the Faraday constant (9.6485×104 C mol−1). For
the reduced and oxidized DTT pair, the standard midpoint potential, E0’, was previously
determined to be −332 mV at pH 7.0 (46). This value was adjusted to pH 7.5 according to the
equation (42, 49)
(2)
The ΔE/ΔpH value for DTT was taken as −61.5 (42).
PRL-1 undergoes a structural transition upon reduction and sequence assignments for the
reduced and oxidized species are published elsewhere (44,45). This information was used to
identify chemical shifts for the same residues in each state and to select reference peaks that
have no change in chemical shift upon reduction (G123; 7.9 and 107.6 ppm and Y126; 9.3 and
124.3 ppm). The reference peaks were used to control for dynamics changes between the two
spectra. The correction factors were averaged for both reference peaks and then applied to the
peaks selected for statistical analysis. 10% of the backbone NH resonances that change intensity
significantly upon reduction were selected on the basis that they were well-resolved and
assigned in both the reduced and oxidized spectra. These peaks were used to calculate E0’ of
PRL-1. The peak heights of individual resonances were normalized, plotted against the half-
cell potential and fit to the following function using Graphpad Prism Software for non-linear
curve fitting (Version 5) (49)
(3)
where A and B are the values for the initial and final plateaus of the sigmoidal decay function
and p is the curve increase rate from the plot of each resonance. The resulting individual curves,
depicting the relative amounts of the corresponding NH resonance in the reduced and oxidized
states, intersect at 50% of the maximal intensity. This point defines the standard potential E’.
15 individual peaks were fit for an E’ value and then averaged to determine the reduction
potential.
Results
Purified Full-length PRL-1-WT Is Inactive
The pNPP activity assay performed on nonreduced, purified wild-type protein revealed that
90% of the protein is inactive under nonreducing conditions. As shown in Figure 1A, PRL-1
requires the addition of a thiol reducing agent for activity. Maximal activity is reached when
10 mM DTT is added to the solution of 1 mg/mL PRL-1. An eight-fold increase in activity is
observed when 10 mM DTT is added to the assay mixture. As a negative control, the PRL-1-
C104S mutant was constructed. This mutant is completely inactive because the nucleophilic
thiol, which is essential for activity, has been removed. Under reducing conditions our activity
data is comparable to the previously published kinetic constants, where truncated forms of
PRL-1 were found to turn over generic PTPase substrates quite slowly (36).
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Because activity was dramatically affected by the addition of reducing agents, we hypothesized
that the lack of signal observed for the untreated PRL-1-WT was due to disulfide bond
formation at the active site. To test this, we ran untreated PRL-1-WT on SDS-PAGE under
non-reducing conditions. Disulfide bond formation can be visualized using non-reducing
SDSPAGE (36). An oxidized protein, containing a disulfide bond, runs at a lower molecular
weight than predicted because the sequence is more compact. When left untreated, wild-type
PRL-1 runs as two bands on an SDS-PAGE gel, just below the 20-kDa marker (Figure 1B,
lane 1). For wild-type PRL-1, the lower band is much more intense, corresponding to a high
degree of oxidation. When run under oxidizing conditions, only the lower band is detected
(Figure 1B, lane 2). The addition of four-fold excess of reduced DTT to the oxidized sample
restores the upper band or reduced species. Disulfide bond formation in PRL-1 has been
observed by SDS-PAGE previously, but these studies were performed on a truncated version
of PRL-1, and hydrogen peroxide was used to accomplish oxidation (36). Because H2O2 also
oxidizes methionine residues rapidly, we chose to use a thiol-specific chemistry for this study.
This approach has the advantage of employing an equilibrium reaction and enables quantitative
analysis. Because glutathione (GSH) is the primary redox buffer in vivo, these experiments
were also performed using the GSH/GSSG redox couple as a thiol modulating agent. Although
GSSG efficiently oxidized PRL-1 (data not shown), complete reduction by GSH was only
accomplished at concentrations near 50 mM (Supporting Information, Figure 1). Because of
this, DTT was used in all studies as both an oxidizing and reducing agent. As a control, the
C104S mutant was also examined. At 50 mM oxidized DTT, no band corresponding to the 20
kDa oxidized species was observed (data not shown), indicating the band at 20 kDa reflects
formation of a disulfide bond between C104 and C49. This is consistent with the findings of
Sun et al., who examined both the C104S and C49S mutant by SDS-PAGE (36).
To confirm the formation and position of disulfide bonds in the untreated full-length protein,
PRL-1 was analyzed using mass spectrometry. Several peaks were observed in the mass spectra
of intact protein, which indicate wild-type PRL-1 is oxidized. A mass shift of +2 is observed
in the spectra of proteins subject to chemical reduction compared to the oxidized samples,
suggesting that one disulfide bond has been broken. To identify the specific sites at which
oxidation occurs, PRL-1 was digested with trypsin and examined using LC-separated ESIMS
under both reducing and oxidizing conditions. Digests of wild-type PRL-1 protein in
nonreducing and reducing environments reveal differences in intensity for peaks associated
with peptides containing C49 and C104. In the presence of oxygen, PRL-1-WT shows almost
exclusively the presence of the C49- and C104-containing fragments joined by a disulfide bond
(Supporting Information, Figure 2A). The disulfide-bound fragment is observed as a large m/
z +1 peak at 3183.3 in the mass spectrum of oxidized PRL-1. The individual C49-containing
fragment expected at m/z +1 1470.6 in oxidized PRL-1-WT is present only as a trace peak.
These two fragments are easily distinguished from other peaks because they are located in
unpopulated regions of the spectrum. In contrast, the 1714 m/z +1 signal calculated for the
C104-containing fragment is buried under other peaks and cannot be easily distinguished
among numerous overlapping signals for this sample. Chemical reduction of PRL-1 with
reducing agent results in complete loss of signal at 3183.3, indicating the disulfide bond
between the two peptides has been broken. Concomitantly, a large peak appears at 1470.6,
which corresponds to the individual C49-containing peptide. Additionally, because the
nucleophilic cysteine may be oxidized to sulfinic and sulfonic acids, MS data were mined for
additional oxidation to the corresponding peptide with two and three oxygen atoms,
respectively. Peaks at the predicted masses were not found in any of the samples, indicating
that the redox inactivation of PRL-1 occurs predominantly through disulfide bond formation
at the catalytic cysteine. A disulfide bond between C104 and C49 has also been reported for
PRL-1 previously and is obvious in the crystal structure of the oxidized form (36, 39).
Collectively, our data show that purified full-length PRL-1-WT is oxidized and, consequently,
requires a reducing agent to restore activity.
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Complete Oxidation of Full-length PRL-1-WT Leads to Precipitation
NMR can be used to determine the reduction potential of a protein (49). An accurate calculation
of the reduction potential of PRL-1 requires an accurate measurement of the NMR peak heights
that correspond to the reduced and oxidized species. This necessitates conversion to either a
completely oxidized or reduced species in order to perform a complete titration and to have an
accurate reference baseline. We chose to completely oxidize PRL-1 because it is predominately
oxidized following purification without treatment of oxidizing agents. Unexpectedly,
incubation of wild-type PRL-1 with oxidizing agents (H2O2, GSSG and/or oxidized DTT)
resulted in complete precipitation of the protein at one hour. Attempts to re-oxidize PRL-1
following reduction with these components also led to precipitation (data not shown). Because
the NMR experiments necessary to complete a redox titration require the protein to remain
stable and soluble for a longer period of time, the wild-type protein was not a suitable candidate
for this study.
Previous studies of PRL-1 indicated that the C-terminus affects solubility (36,39). As such, we
anticipated that precipitation could be avoided by using a C-terminal mutant, to perform the
redox titration. We first investigated the activity of the PRL-1-C170S-C171S mutant and
performed a pNPP activity assay. In stark contrast to untreated wild-type PRL-1, the untreated
C170S-C171S mutant exhibits an eight-fold increase in activity (Figure 2A). The activity of
PRL-1-C170S-C171S is statistically identical to wild-type PRL-1 under reducing conditions,
and the activity of this mutant is not modulated by the addition of reducing agents. Taken
together, these data indicate that the active-site cysteine in the C170S-C171S mutant remains
primarily reduced. To confirm this, we performed a trypsin digest and analyzed the peptides
by mass spectrometry. The digest of untreated PRL-1-C170S-C171S shows disulfide-linked
peptides only at equivalent intensity to background (Supporting Information, Figure 2B),
suggesting no specific disulfide formation between the C49 and C104-containing peptides
occurs. Conversely, the individual C49-containing peptide is exclusively detected. The MS
spectrum for PRL-1-C170S-C171S is identical under non-reducing and reducing conditions,
as no change in the signal for either mass is observed following addition of reducing agent.
We next investigated the ability to oxidize PRL-1-C170S-C171S. When left untreated, PRL-1-
C170S-C171S also runs as two bands on an SDS-PAGE gel; however, the upper band, which
corresponds to reduced PRL-1, is much more intense than the lower band (Figure 2B-lane 6).
We attempted to oxidize PRL-1-C170S-C171S. Based on the intensity of the reduced and
oxidized bands on SDS-PAGE, we estimated that this mutant requires at least 20-fold more
oxidizing agent than WT (Figure 2, compare panel B to C). This finding indicates that PRL-1-
C170S-C171S is much less susceptible to oxidation than WT. We did not attempt to quantify
the reduction potential of this protein because, surprisingly, incubation of PRL-1-C170S-
C171S with oxidizing agents also results in complete precipitation of the protein at one hour
(data not shown). Instead we pursued identification of a PRL-1 variant that would allow us to
determine the active-site reduction potential of full-length PRL-1. We investigated the role of
the remaining two Cysteines, C98 and C99, in PRL-1 solubility. The crystal structure of PRL-1
reveals that C98 and C99 are largely buried in the hydrophobic core of the protein, but the side
chain of C98 is partially surface-accessible. We hypothesized that oxidation of C98 might lead
to formation of a second disulfide bond and cause a structural transition, leading to
precipitation. To investigate this hypothesis, we mined the NMR and MS data more closely.
The Cβ NMR chemical shift of a cysteine residue can be used to deduce the oxidation state of
the thiol moiety. The chemical shift of an oxidized side chain (disulfide bound) should have a
downfield shift closer to that of the Cα resonance (53). The Cβ chemical shift of C98 in
untreated wild-type PRL-1 indicates that this residue is reduced (26.449 ppm). For comparison,
the Cβ chemical shifts of the disulfide bound C49 and C104 residues are 35.21 ppm and 36.36
ppm, respectively. Reduction of PRL-1 leads to a large change in Cβ chemical shifts for the
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C49 and C104 residues (34.01 ppm and 29.82 ppm, respectively). Cβ chemical shift
information is unavailable for residue C99 in the oxidized state and is likely absent due to
chemical exchange (45).
To further investigate the propensity of C98 and C99 to be oxidized we examined the MS data
of wild type and PRL-1-C170S-C171S. Digested PRL-1-C170S-C171S shows a strong signal
for the peptide containing C104 at 1712. The observed value is 2 amu below the predicted mass
of 1714. This mass, which is shifted by −2, also is consistently observed in the spectra of the
cross-linked species involving the C49- and C104-containing peptides (3181.3) derived from
non-reduced wild-type PRL-1. Addition of reducing agent shifts the mass of the C104-
containing peptide to 1714 for both wild type and PRL-1-C170S-C171S. Because the C104-
containing peptide also includes C98 and C99, it is likely that an intra-peptide disulfide bond
between C98 and C99 is also present. MS analysis of intact PRL-1 under non-reducing
conditions reveals a peak 4 amu below the calculated mass, and this peak shifts to the expected
position in the MS spectrum upon addition of reducing agent when no LC separation is
performed. As such, it appears that this additional disulfide bond forms after the reducing agent
is removed, likely during the LC step.
PRL-1-C98A Does Not Precipitate and Is Structurally and Functionally Equivalent to PRL-1-
WT
Because the MS data indicate the possibility of C98-C99 disulfide bond formation upon
oxidation, we created the PRL-1-C98A mutant. We hypothesized that chemical oxidation by
thiol modulating agents leads to oxidation of the C98 and C99 residues in both PRL-1-WT and
PRL-1-C170S-C171S, which results in precipitation. Mutation of C98 mitigates this problem.
Untreated PRL-1-C98A runs similarly to PRL-1-WT on SDS-PAGE (Figure 3A, compare lane
1 to 4). Like wild-type PRL-1, complete oxidation of PRL-1-C98A occurs with 5 mM oxidized
DTT and is re-reduced by addition of a four-fold excess of reduced DTT (Figure 3A, compare
lane 2 to 5 and 3 to 6). Unlike wild type, incubation of C98A with oxidizing agents for extended
periods of time results in little to no precipitation. Consequently, PRL-1-C98A was found to
be an appropriate candidate to use for a reversible, equilibrium redox titration. To ensure that
this mutation has not compromised the functional or structural integrity of the protein, we
compared the PTPase activity and NMR spectra of PRL-1-WT to PRL-1-C98A.
Wild type and C98A exhibit almost identical substrate turnover when assayed in equivalent
redox conditions. PRL-1-C98A shows an equivalent level of activity when left untreated.
Oxidation of the protein with 5 mM oxidized DTT completely abolishes the activity of the
enzyme (data not shown), while reduction with 10 mM DTT recovers the full activity of this
mutant, as shown by comparison to the reduced wild type and C170S-C171S mutant (Figure
3B). The percent activity of PRL-1-C98A under oxidizing conditions was determined to be
0.05 ± 2% and was not included in the figure. Activity of the wild-type protein under oxidizing
conditions was not measured because the formation of the precipitant precludes accurate
measurement of the assay product.
To verify the C98A mutation does not significantly alter the protein structure, we
collected 1H-15N HSQC spectra of wild type and PRL-1-C98A. The HSQC experiment is
particularly useful for the analysis of protein structure because the experiment selectively
detects those protons directly coupled to nitrogen. One cross peak is observed for every amide
in the protein at a position characterized by its 1H and 15N chemical shifts. The HSQC spectrum
provides an overall map or fingerprint of the protein backbone and serves as the basis for
assessing the overall fold and behavior of a protein. Because chemical shift is so sensitive to
environment, changes in a protein’s tertiary structure are reflected by changes in the peak
positions in the HSQC spectrum (54). Comparison of the HSQC spectra of wild type and
PRL-1-C98A reveals relatively small changes between the two variants (Figure 4A). As such,
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the overall structure of PRL-1-C98A and PRL-1-WT are virtually identical, as indicated by
the large number of peaks in common in these two spectra. Based on the previously reported
assignments for full-length oxidized PRL-1-WT and the previously published crystal structure
of truncated PRL-1-WT (36,45), significant chemical shift changes correspond to residues
located near the site of the mutation (Figure 4A, black boxes and Figure 4B). The average
chemical shift deviation (Δδavg) for PRL-1-WT and PRL-1-C98A was calculated by
subtracting the chemical shift values of the C98A mutant from those of the wild type and was
determined to be 0.07 ppm for 15N and 0.01 ppm for 1H. It should be noted that several new
peaks appear in the spectrum of PRL-1-C98A that are not observed for wild type. Peaks for
many of the C-terminal residues in PRL-1-WT were absent from the HSQC spectrum, likely
because of line broadening due to exchange on the intermediate timescale. We suspect the new
peaks in the PRL-1-C98A spectrum are resonances from the C-terminus, and their appearance
may reflect a faster rate of exchange on which the motions at these residues occur in the PRL-1-
C98A protein. Sequential backbone assignments of the C98A mutant and complete dynamics
analysis of both are needed to confirm this, which is beyond the scope of this paper.
We previously reported that reduction of PRL-1 results in a conformational change, causing
greater than 90% of the peaks in the wild-type spectrum to move. We obtained backbone
chemical shift assignments for both the oxidized and reduced forms, which are reported
elsewhere (44,45). The PRL-1-C170S-C171S was used to assign the reduced state because
active site residues were absent from or too weak to assign in the spectra of the chemically
reduced wild type. The most dramatic change in the spectrum that occurs upon reduction of
PRL-1 corresponds to C49. The position of C49 in the HSQC shifts significantly upfield by
more than 9 ppm in nitrogen and 1 ppm in proton compared to the oxidized form. Figure 5
maps the observed changes in chemical shifts (Δδ) of assigned resonances to the available
crystal structure of oxidized PRL-1. Δδ values were obtained by subtracting the chemical shift
of PRL-1-C170S-C171S from those of wild-type PRL-1 (Supporting Information, Table 1). A
Δδavg of 0.91 ppm for 15N and 0.24 ppm for 1H was determined for these two forms of the
protein. Parallel changes in chemical shifts are observed upon reduction of PRL-1-C98A
(Supporting Information, Figure 3). The Δδavg value was determined to be 0.72 for 15N and
0.14 for 1H by subtracting the chemical shifts of the reduced protein from those of the oxidized
protein, which is in strong agreement between that observed for wild type and PRL-1-C170S-
C171S and confirms that redox modulation at the active site in C98A parallels that of wild
type. Collectively, our structural and functional comparisons have shown that PRL-1-C98A is
an appropriate analog of the PRL-1 system, from which the reduction potential of the active-
site disulfide bond can be determined.
Determining the Reduction Potential of the C49-C104 Disulfide Bond in Full-length PRL-1
To determine the reduction potential, oxidized PRL-1 (in the presence of 5 mM oxidized DTT)
was gradually reduced by the addition of reduced DTT to a concentration of 200 mM. The
peak heights of the following residues were monitored and analyzed as described: V12, R18,
L30, T43, R47, C49, V65, L66, I80, R93, I100, A101, L114, E127, and Y152. Peak selection
was based on spectral resolution, proximity to the disulfide bond, distance from mutation site
and chemical exchange behavior (slow exchanging peaks only). Figure 6 displays a
representative plot, depicting the results of the titration on residue C49, in which normalized
peak height is plotted vs. half-cell potential. Similar results were obtained for all other residues
and the chemical shifts of each residue in both states are included in Table 1. An average E’
value of −364.3 ± 1.5 mV was calculated for the C49-C104 disulfide bond using the data from
15 residues.
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The reduction potential of the active site disulfide bond in full-length PRL-1 was determined
to be approximately −365 mV at pH 7.5. The reported reduction potentials determined for
various cellular environments range from −320 (most reducing) to −170 mV (most oxidizing),
the details of which have been reviewed extensively (42,55–58). Based on these values, our
results indicate that nascent PRL-1 is rapidly oxidized inside the cell to an inactive state. The
reduction potential is considerably lower than those reported for proteins that are known to
play an important role in maintaining the redox state of the cell and/or specific proteins. The
reduction potential of thioredoxin-1 (Trx-1), found in the cytoplasm and nucleus, has been
reported to be −230 mV, while that of Trx-2, found in the mitochondria, is near −330 mV
(55,59). Both enzymes would have a substantial fraction of protein in the active state in their
respective environments, and Trx-1 would be able to act as a reducing agent more effectively
in the nucleus. Reduction potentials for cytoplasmic glutaredoxins (Grx) vary depending on
the primary sequence and range from −200 to −240 mV (60). Reduction potentials for proteins
that facilitate disulfide bond formation in the endoplasmic reticulum have been determined to
be −175 mV (protein disulfide isomerase; PDI) and −275 mV (regulatory disulfide of Ero1α)
(61,62). The role of PDI is to make and break disulfide bonds in target proteins and the reduction
potential is appropriate for this enzyme in this compartment. The reduction potential of
Ero1α is sufficiently negative to ensure oxidation and facilitate re-oxidation of PDI. To date,
analysis of reduction potentials has been focused on a small subset redox modulating enzymes,
but measuring the reduction potentials of other proteins that are subject to redox regulation has
recently been recognized as important as well. The absence of general and accurate methods
for quantifying these potentials has precluded the ability to identify conditions in which
proteins are switched on or off by disulfide bond formation. NMR spectroscopy has recently
been shown to be a valuable tool for obtaining this information and was used to determine the
reduction potential of Trx-1 with great accuracy (49). Other proteins have been studied using
this method as well. Zimmerman et al. used NMR to determine the reduction potential of the
N-terminal hSH3 domain of the immune cell protein ADAP (adhesion and degranulation
promoting adapter protein) (63). Sahu et al. used NMR to quantify the reduction potential of
the High Mobility Group B1 (HMGB1) protein, which plays an important role in DNA binding
as well as chemotaxis (64). In both examples, disulfide bond formation was shown to lead to
a conformational change, which alters the function of the protein. The altered function of the
protein also correlates with a change in subcellular location. Likewise, the subcellular location
of PRL-1 may affect the activity of the protein, although no cellular compartment is sufficiently
negative to ensure activation. Even in the most reducing environment reported (−320 mV),
nascent PRL-1 would exist primarily in an inactive, oxidized state (> 96%). This strongly
suggests that in vivo, PRL-1 likely requires a posttranslational modification or binding partner
to switch on phosphatase activity.
The data presented here demonstrate the importance of the C-terminus to the phosphatase
activity of PRL-1 and show that modification of the C-terminus affects the redox state of the
active site, making PRL-1 much less susceptible to inactivation (Figure 2). The PRL enzymes
each contain a C-terminal prenylation motif or CaaX box (C stands for cysteine, a represents
any aliphatic residue and X corresponds to any amino acid). The prenylation motif directs
farnesylation at the conserved CaaX box cysteine, followed by proteolytic cleavage of the aaX
peptide and methylation of the terminal carboxyl moiety (65). Farnesylation has been shown
to occur in vivo for the PRL enzymes (6,9,14). In PRL-1, this modification occurs at C170.
Based on our data, the shift in the reduction potential of the inactivating disulfide bond in
PRL-1 to a less negative value appears to be accomplished through a conformational change
that depends on the presence of C-terminal residues in the CaaX box. Because farnesylation
occurs on C170 and mutation of this residue makes PRL-1 less prone to inactivation, we expect
farnesylation will also alter the protein’s conformation and reduction potential of the active
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site disulfide bond. Because farnesylation often leads to membrane association and PRL-1 has
been shown to localize to several membranes in vivo (6,8,14,16,36,39), the protein’s
conformation may be altered more substantially in the context of a lipid bilayer than is apparent
from solution studies.
In all work published to date, the phosphatase activity of PRL-1 has been reported to be
necessary for the promotion of cellular proliferation and motility by this protein, regardless of
localization (7–9,26,30,33,34). PRL-1 is typically farnesylated in cells (6,9,14,24) and
farnesylated PRL-1 is most often directed to the nucleus (9,13,43). The fact that PRL-1 is most
often localized to the nucleus seems appropriate with respect to cellular redox conditions (2,
5,10), because this compartment is often the most reducing organelle at −320 mV (55). Based
on our studies of the C-terminal mutant, it seems that modification at the C-terminus would
likely raise the reduction potential sufficiently to turn on phosphatase activity in this
environment. Interestingly, when farnesylation of PRL-1 is prevented in cells, the ability of
this protein to promote proliferation is abrogated and its localization is often altered. For
example, the lack of prenylation inhibits the ability of PRL-1 to promote invasion and motility
of SW480 colon carcinoma cells and to promote HEK293 cell growth and migration (8,24).
In these cases, it was not determined whether localization and/or PTPase activity is responsible
for the altered phenotype. In mitotic cells, however, PRL-1 localizes to the centrosomes and
spindle apparatus independent of whether farnesylation occurs, and despite proper localization,
farnesylation deficient mutants result in mitotic defects (9). Interestingly, the inactive mutant
produced the same result. During mitosis, the nuclear envelope breaks down and the reduction
potential of the cell becomes approximately −240 mV (42,66,67). The reduction potential of
unmodified PRL-1 (−365 mV) is much too low to be active in this redox environment. As such,
farnesylation may enhance PRL-1 activity during mitosis, and this may explain why mitotic
defects were observed with both the catalytically inactive C104 mutant and non-farnesylated
proteins.
PRL-1 facilitates the regeneration of damaged tissue by promoting proliferation and migration,
notably in the liver, which has a highly reducing environment. Increased activity in this case
may be due, at least in part, to elevated expression of the protein (2). The expression and
phosphatase activity of PRL-1 have also been associated with many types of cancer cell lines
(12,13,16,17,23). It has been well documented that cancer cells are generally more reducing
than their normal counterparts (68–70). Because cancer cells have aberrantly regained the
ability to proliferate and have lost the ability to maintain redox homeostasis (42), we
hypothesize that the redox environment in some cancer cells may be sufficiently negative to
confer activity in PRL-1. This is supported by the fact that abolishing the activity of PRL-1 in
cancer cell lines by transfecting them with catalytically inactive PRL mutants decreases cell
viability, prevents cells from entering into mitosis and also inhibits anchorage independent
growth (8,9). These and other studies collectively suggest that the active form of PRL-1 may
be a good target for therapeutic intervention in the treatment of metastatic cancers (12).
It is clear from our in vitro studies that changes in cellular redox conditions will have a profound
affect on the activity of PRL-1 in vivo and that modification of residues, especially at the C-
terminus, may dramatically alter the propensity of PRL-1 to be oxidized and inactivated inside
the cell. Given its diverse localization and multifarious roles in proliferation, differentiation
and motility, the data presented here provides the impetus to pursue further studies that
investigate the function of PRL-1 under distinct cellular conditions in order to generate a more
accurate account of how PRL-1 is regulated in vivo and how its regulation contributes to such
diverse cellular outcomes.
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A. The activity of PRL-1-WT was measured using a standard pNPP activity assay (see methods
section). The amount of product formed at one hour was calculated and used to assess the
relative activity of PRL-1-WT and PRL-1-C104S, an inactive form of PRL-1. The activity of
PRL-1-C104S was identical to that of background pNPP (data not shown). Data are displayed
as percent maximum activity (100%) based on the average of reduced PRL-1-C170S-C171S
samples, following subtraction of the blank involving the inactive PRL-1-C104S mutant.
PRL-1-WT requires 10 mM reducing agent for optimal activity. The activity of PRL-1-WT
with 10 and 50 mM DTT were statistically identical, and no further increase in activity was
observed when 100 and 200 mM reduced DTT were added (data not shown). B. 2 mg/mL
PRL-1-WT was incubated with various amounts of oxidized or reduced DTT for approximately
one hour. PRL-1 runs as two bands on non-reducing SDS-PAGE corresponding to reduced
(upper) and oxidized (lower) forms of the protein (lane 1). The higher intensity of the lower
band indicates that untreated PRL-1-WT is primarily oxidized. The addition of 5 mM oxidized
DTT sufficiently oxidizes PRL-1-WT (lane 2). This was determined by titrating increasing
amounts of oxidized DTT (0.01–10 mM) (data not shown). The addition of 20 mM reduced
DTT to the reaction mixture recovers reduced PRL-1-WT (lane 3). The final oxidized to
reduced DTT concentration ratio was 4:1. All samples contained 50 mM sodium phosphate
buffer and 100 mM NaCl at pH 7.5.
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A. The activity of PRL-1-C170S-C171S was measured as described in Figure 1. The activity
of PRL-1-C170S-C171S is not modulated by the addition of DTT and is statistically identical
under both non-reducing and reducing conditions. There is also no statistically significant
difference in activity between the reduced wild type and PRL-1-C170S-C171S mutant,
indicating that this mutant is primarily in the reduced state even in the absence of thiol
modulating agents. B. PRL-1-C170S-C171S was run on SDS-PAGE under various oxidizing
conditions (0–5 mM oxidized DTT). Under non-reducing conditions (lane 6), C170S-C171S
runs as two bands. In contrast to wild type, however, C170S-C171S is primarily reduced as
indicated by the much greater intensity of the upper reduced band. The small amount of
oxidized protein is reduced upon addition of 3 mM DTT (data not shown). Complete oxidation
of PRL-1-C170-171S occurs near 2 mM oxidized DTT. C. PRL-1-WT was run on SDS-PAGE
under the same conditions as in B. Complete oxidation of wild type occurs near 0.1 mM
oxidized DTT. In both B and C panels, samples were prepared as in figure 1.
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A. Lanes 1–3 are the same samples from the gel shown in Figure 1B and are included here for
ease of comparison. Lanes 4–6 were run under the same conditions as described for Figure 1.
PRL-1-C98A behaves much like PRL-1-WT. When left untreated, it runs as two bands
corresponding to both reduced (upper) and oxidized (lower) forms. Oxidation of PRL-1-C98A
also occurs in 5 mM oxidized DTT. This was determined in the same manner as for wild type.
Re-reduction of PRL-1-C98A occurs at the same ratio (4:1) as PRL-1-WT. B. The measured
activities of PRL-1-WT and PRL-1-C98A are equivalent within error prior to addition of
reducing agent, and each is completely activated by the addition of 10 mM reduced DTT. This
is in contrast to the PRL-1-C170S-C171S mutant, which is not modulated by the addition of
reducing agent. The activities of reduced WT, C98A and C170S-C171S are identical within
error. The activity of PRL-1-C98A under oxidizing conditions (5 mM oxidized DTT) was
equivalent to that of PRL-1-C104S (data not shown).
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Figure 4. Comparisons of PRL-1-WT and C98A
A. The spectrum of untreated PRL-1-WT (red) is overlaid with untreated PRL-1-C98A (black).
Small differences in structure exist between these two proteins, and the residues that change
significantly with mutation are enclosed in boxes. Unlabeled boxes enclose either new peaks
in C98A (black) or unassigned peaks in wild type (red). B. The chemical shift changes observed
between these two proteins were mapped to the available crystal structure of the oxidized wild
type. A break in the structure exists between residues F70 and G73 because no information is
available for D71 and D72 residues. F70 and G73 are labeled and colored in pink to illustrate
the break. For chemical shift mapping, the Δδ value for all assigned residues was used as the
b-factor in the pdb file (1ZCK). Δδ was determined by subtracting the reduced chemical shift
from that of the oxidized. Residues for which an assignment is missing in one of the two states
are colored white. The rainbow color scale is applied with the largest changes being highlighted
in red and insignificant changes in blue. Additionally, larger changes in chemical shift
correspond to an increase in tube diameter. This figure was generated using Pymol.
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Figure 5. Comparisons of PRL-1-WT and C170S-C171S
A. Differences in NMR chemical shifts between PRL-1-WT and PRL-1-C170-C171S were
mapped to the crystal structure (as in figure 4) and displayed with the active site in front. The
disulfide bound (pink bond) C104 and C49 are labeled. F70 and G73 are labeled to identify
the break in the crystal structure. B. As in A, but with the active site rotated downward by
approximately 90 degress to reveal the large number of chemical shift deviations in the majority
of the protein structure, especially in the central β-strand. Both figures were generated using
Pymol.
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Figure 6. Representative Plot of Reduction Potential Derived From Residue C49
The peak heights of residue C49 were normalized and plotted versus the half-cell potential of
DTT, which was determined using the Nernst equation. The value determined for this residue
was −364.4 ± 0.7 mV. Similar results were obtained for other residues and are listed in Table
1.
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